Immunomodulators Market: By Product Immunostimulants By Application and Region Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Immunomodulators Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Immunosuppressants (Antibodies, Calcineurin inhibitors, Glucocorticoids, Antimetabolites) Immunostimulants (Vaccines, Antibodies) By Application (Oncology, Respiratory, HIV) and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Immunomodulators Market size was valued at US$ 231.0 million in 2024 and is expected to reach US$ 351.9 million by 2031, growing at a significant CAGR of 6.2% from 2025-2031. The global market provides a detailed overview of the market and that can be segmented by product and application. By product, the market has been segmented into immunosuppressants and immunostimulants. The immunosuppressants segment is likely to be the largest and fastest-growing segment in terms of product. The immunosuppressants segment is further segmented into antibodies, calcineurin inhibitors, glucocorticoids, and antimetabolites. Immunostimulants is segregated into vaccines and antibodies. Based on application, the market is segmented into oncology, respiratory, and HIV. Among these, the oncology segment is expected to have the fastest-growing market during the forecast period.

Key Developments

  • In Feb 2021, PFIZER and BioNTech have begun research to eliminate COVID-19 boosters and new vaccine varieties as part of a bigger development plan.

summary download arrow Download Sample

Immunomodulators Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

6.2%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Immunomodulators Market Dynamics

The rising prevalence of chronic diseases like as asthma, cancer, allergy ailments, and multiple sclerosis is a major contributor to the market's expansion. In addition, the increased use of early immunomodulator therapy for the treatment of Crohn's disease is boosting the market's growth. The availability of significant unmet clinical requirements in the treatment of immunological illnesses, such as rheumatoid arthritis, is driving this vertical's expansion.

Immunomodulators Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 231.0 million

Market Size in 2031

US$ 351.9 million

Market CAGR

6.2%

By Product

  • Immunosuppressants
  • Immunostimulants

By Application

  • Oncology,
  • Respiratory,
  • HIV

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The immunomodulators market provides granular level information about the market size, regional market share, historic market (2020 to 2024) and forecast (2025 to 2031)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Immunomodulators market size was valued at US$ 231.0 million in 2024 and is expected to reach US$ 351.9 million by 2031, growing at a significant CAGR of 6.2%.

The major players in the market are Hoffmann-La Roche Ltd (Basel, Switzerland), Novartis AG (Basel, Switzerland), Biogen (Massachusetts, U.S.), Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel), Amgen, Inc (California, U.S.), Bristol-Myers and Squibb Company (New York, U.S), Merck Sharp and Dohme Corp. (New jersey, U.S) and Eli Lilly and Company (Indiana, U.S).

Asia Pacific is the fastest-growing region for the market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Immunomodulators Market Introduction
2.1. Global Immunomodulators Market - Taxonomy
2.2. Global Immunomodulators Market -Definitions
2.2.1. By Product
2.2.2. By Application
2.2.3. By Region
3. Global Immunomodulators Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Immunomodulators Market Dynamic Factors - Impact Analysis
3.6. Global Immunomodulators Market - Competition Landscape
4. Global Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Immunomodulators Market, By Product, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
5.1. Immunosuppressants
5.1.1. Antibodies
5.1.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Calcineurin inhibitors
5.1.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Glucocorticoids
5.1.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Antimetabolites
5.1.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Immunostimulants
5.2.1. Vaccines
5.2.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Antibodies
5.2.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Others
5.2.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
6. Global Immunomodulators Market, By Application, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
6.1. Oncology
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Respiratory
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. HIV
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Immunomodulators Market Forecast, By Region, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Region, 2024 - 2030
8. North America Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
8.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Immunosuppressants
8.1.1.1. Antibodies
8.1.1.2. Calcineurin inhibitors
8.1.1.3. Glucocorticoids
8.1.1.4. Antimetabolites
8.1.1.5. Others
8.1.2. Immunostimulants
8.1.2.1. Vaccines
8.1.2.2. Antibodies
8.1.2.3. Others
8.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Oncology
8.2.2. Respiratory
8.2.3. HIV
8.2.4. Others
8.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030
8.5. North America Immunomodulators Market Dynamics - Trends
9. Europe Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
9.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Immunosuppressants
9.1.1.1. Antibodies
9.1.1.2. Calcineurin inhibitors
9.1.1.3. Glucocorticoids
9.1.1.4. Antimetabolites
9.1.1.5. Others
9.1.2. Immunostimulants
9.1.2.1. Vaccines
9.1.2.2. Antibodies
9.1.2.3. Others
9.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oncology
9.2.2. Respiratory
9.2.3. HIV
9.2.4. Others
9.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030
9.5. Europe Immunomodulators Market Dynamics - Trends
10. Asia-Pacific Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
10.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Immunosuppressants
10.1.1.1. Antibodies
10.1.1.2. Calcineurin inhibitors
10.1.1.3. Glucocorticoids
10.1.1.4. Antimetabolites
10.1.1.5. Others
10.1.2. Immunostimulants
10.1.2.1. Vaccines
10.1.2.2. Antibodies
10.1.2.3. Others
10.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oncology
10.2.2. Respiratory
10.2.3. HIV
10.2.4. Others
10.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030
10.5. Asia-Pacific Immunomodulators Market Dynamics - Trends
11. Latin America Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
11.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Immunosuppressants
11.1.1.1. Antibodies
11.1.1.2. Calcineurin inhibitors
11.1.1.3. Glucocorticoids
11.1.1.4. Antimetabolites
11.1.1.5. Others
11.1.2. Immunostimulants
11.1.2.1. Vaccines
11.1.2.2. Antibodies
11.1.2.3. Others
11.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oncology
11.2.2. Respiratory
11.2.3. HIV
11.2.4. Others
11.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030
11.5. Latin America Immunomodulators Market Dynamics - Trends
12. Middle East and Africa Immunomodulators Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031 (Revenue, USD Mn) 
12.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Immunosuppressants
12.1.1.1. Antibodies
12.1.1.2. Calcineurin inhibitors
12.1.1.3. Glucocorticoids
12.1.1.4. Antimetabolites
12.1.1.5. Others
12.1.2. Immunostimulants
12.1.2.1. Vaccines
12.1.2.2. Antibodies
12.1.2.3. Others
12.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oncology
12.2.2. Respiratory
12.2.3. HIV
12.2.4. Others
12.3. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Immunomodulators Market - Opportunity Analysis Index, By Product, Application, and Country, 2024 - 2030
12.5. MEA Immunomodulators Market Dynamics - Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Hoffmann-La Roche Ltd (Basel, Switzerland)
13.2.2. Novartis AG (Basel, Switzerland)
13.2.3. Biogen (Massachusetts, U.S.)
13.2.4. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
13.2.5. Amgen, Inc (California, U.S.)
13.2.6. Bristol-Myers and Squibb Company (New York, U.S)
13.2.7. Merck Sharp and Dohme Corp. (New jersey, U.S)
13.2.8. Eli Lilly and Company (Indiana, U.S)
14. Research Methodology
15. Key Assumptions and Acronyms

Key Market Players

  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Novartis AG (Basel, Switzerland)
  • Biogen (Massachusetts, U.S.)
  • Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
  • Amgen, Inc (California, U.S.)
  • Bristol-Myers and Squibb Company (New York, U.S)
  • Merck Sharp and Dohme Corp. (New jersey, U.S)
  • Eli Lilly and Company (Indiana, U.S)

Related Industry Reports

Her2 Antibodies Market

Immunosuppressants Market